A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma

被引:6
|
作者
Liu, Zhenyang [1 ,2 ]
Ahn, Michael Ho-Young [1 ]
Kurokawa, Tomohiro [1 ]
Ly, Amy [3 ]
Zhang, Gong [1 ]
Wang, Fuyou [1 ]
Yamada, Teppei [1 ]
Sadagopan, Ananthan [1 ]
Cheng, Jane [1 ]
Ferrone, Cristina R. [1 ,4 ]
Liss, Andrew S. [4 ]
Honselmann, Kim C. [4 ]
Wojtkiewicz, Gregory R. [5 ]
Ferrone, Soldano [1 ,6 ]
Wang, Xinhui [1 ]
机构
[1] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Div Surg Oncol, Boston, MA 02115 USA
[2] Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, Dept Gastroenterol & Urol & Med Oncol, Changsha, Hunan, Peoples R China
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA
[4] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Div Gen & Gastrointestinal Surg, Boston, MA 02115 USA
[5] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Syst Biol, Mouse Imaging Program, Boston, MA 02115 USA
[6] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA
关键词
PDX expansion; Subcutaneous PDX mouse model; Orthotopic PDX mouse model; PDAC PDX; CANCER; TISSUE; PLATFORM; TRIAL;
D O I
10.1186/s12967-020-02414-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background Patient-derived xenograft (PDX) mouse models of cancer have been recognized as better mouse models that recapitulate the characteristics of original malignancies including preserved tumor heterogeneity, lineage hierarchy, and tumor microenvironment. However, common challenges of PDX models are the significant time required for tumor expansion, reduced tumor take rates, and higher costs. Here, we describe a fast, simple, and cost-effective method of expanding PDX of pancreatic ductal adenocarcinoma (PDAC) in mice. Methods We used two established frozen PDAC PDX tissues (derived from two different patients) and implanted them subcutaneously into SCID mice. After tissues reached 10-20 mm in diameter, we performed survival surgery on each mouse to harvest 90-95% of subcutaneous PDX (incomplete resection), allowing the remaining 5-10% of PDX to continue growing in the same mouse. Results We expanded three consecutive passages (P1, P2, and P3) of PDX in the same mouse. Comparing the times required for in vivo expansion, P2 and P3 (expanded through incomplete resection) grew 26-60% faster than P1. Moreover, such expanded PDX tissues were successfully implanted orthotopically into mouse pancreases. Within 20 weeks using only 14 mice, we generated sufficient PDX tissue for future implantation of 200 mice. Our histology study confirmed that the morphologies of cancer cells and stromal structures were similar across all three passages of subcutaneous PDX and the orthotopic PDX and were reflective of the original patient tumors. Conclusions Taking advantage of incomplete resection of tumors associated with high local recurrence, we established a fast method of PDAC PDX expansion in mice.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma
    Zhenyang Liu
    Michael Ho-Young Ahn
    Tomohiro Kurokawa
    Amy Ly
    Gong Zhang
    Fuyou Wang
    Teppei Yamada
    Ananthan Sadagopan
    Jane Cheng
    Cristina R. Ferrone
    Andrew S. Liss
    Kim C. Honselmann
    Gregory R. Wojtkiewicz
    Soldano Ferrone
    Xinhui Wang
    [J]. Journal of Translational Medicine, 18
  • [2] Defining and tracing subtypes of patient-derived xenograft models in pancreatic ductal adenocarcinoma
    Hyun, Sangyeop
    Han, Youngmin
    Moon, Jae Yun
    Suh, Young-Ah
    Yun, Won-Gun
    Kwon, Wooil
    Lee, Jong-Eun
    Kim, Daeun
    Ku, Ja-Lok
    Jang, Jin-Young
    Park, Daechan
    [J]. CANCER COMMUNICATIONS, 2024, 44 (08) : 921 - 925
  • [3] Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
    Miller, Aubrey L.
    Garcia, Patrick L.
    Gamblin, Tracy L.
    Vance, Rebecca B.
    Yoon, Karina J.
    [J]. CANCER DRUG RESISTANCE, 2020, 3 (03) : 572 - 585
  • [4] Characterization of a collection of patient-derived xenograft models for pancreatic ductal adenocarcinoma translational research
    Yanez, Mariana
    Arenas, Enrique Javier
    Macarulla, Teresa
    Tian, Tian
    Arribas, Joaquin
    Llorente, Sofia
    Fabregat, Carles
    Escorihuela, Marta
    Castet, Florian
    Querol, Jessica
    Salcedo, Maria Teresa
    [J]. CANCER RESEARCH, 2024, 84 (02)
  • [5] Acoustic Cluster Therapy enhances the efficacy of chemotherapeutic regimens in patient-derived xenograft mouse models for pancreatic ductal adenocarcinoma
    Ng, Serina
    Healey, Andrew
    Kvale, Svein
    Kotopoulis, Spiros
    Von Hoff, Daniel D.
    Sontum, Per Christian
    Han, Haiyong
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [6] Isolation and Characterization of Patient-derived Pancreatic Ductal Adenocarcinoma Organoid Models
    Tiriac, Herve
    French, Randall
    Lowy, Andrew
    [J]. JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2020, (155):
  • [7] Enhancing efficacy of gemcitabine in pancreatic patient-derived xenograft mouse models
    Inkoom, Andriana
    Ndemazie, Nkafu
    Affram, Kevin
    Smith, Taylor
    Zhu, Xue
    Underwood, Patrick
    Krishnan, Sunil
    Ofori, Edward
    Han, Bo
    Trevino, Jose
    Agyare, Edward
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS-X, 2020, 2
  • [8] Circulating Tumor Cells as a Biomarker of Response to Treatment in Patient-Derived Xenograft Mouse Models of Pancreatic Adenocarcinoma
    Torphy, Robert J.
    Tignanelli, Christopher J.
    Kamande, Joyce W.
    Moffitt, Richard A.
    Loeza, Silvia G. Herrera
    Soper, Steven A.
    Yeh, Jen Jen
    [J]. PLOS ONE, 2014, 9 (02):
  • [9] Expression of Hedgehog pathway molecules in patient-derived pancreatic adenocarcinoma xenograft models
    Vuarogueaux, Vincent
    Misters, Simon
    Fiebig, Heinz-Herbert
    Foucault, Frederic
    Beckers, Thomas
    [J]. CANCER RESEARCH, 2011, 71
  • [10] The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models
    Garcia, P. L.
    Miller, A. L.
    Kreitzburg, K. M.
    Council, L. N.
    Gamblin, T. L.
    Christein, J. D.
    Heslin, M. J.
    Arnoletti, J. P.
    Richardson, J. H.
    Chen, D.
    Hanna, C. A.
    Cramer, S. L.
    Yang, E. S.
    Qi, J.
    Bradner, J. E.
    Yoon, K. J.
    [J]. ONCOGENE, 2016, 35 (07) : 833 - 845